The present invention relates to substantially planar vascularized brain cancer organoid and methods of using such vascularized brain cancer organoids in anti-cancer drug discovery screen. In particular, provided herein are methods of producing and using complex, highly uniform vascularized brain cancer organoids that comprise physiologically relevant human cells and have the high degree of sample uniformity and reproducibility required for use in high-throughput screening applications.

An object of the present invention is to provide a method of producing a cell population comprising mesenchymal stem cells, comprising efficiently isolating a cell population comprising mesenchymal stem cells at high purity from an amnion. Provided is a method of producing a cell population comprising amnion-derived mesenchymal stem cells, comprising (1) storing an amnion in a medium for 4 hours or longer at 1 C. or higher and 25 C. or lower, followed by (2) isolating the amnion from the medium and treating the amnion with an enzyme; and (3) culturing a cell fraction comprising mesenchymal stem cells after the treatment with the enzyme.

A method for treating a subject having a medical conditions associated with inflammation and/or an unwanted immune response, and said subject does not have an alpha1-antitrypsin (AAT) deficiency, wherein the method includes administering genetically modified mesenchymal stem cells to the subject, wherein said genetically modified mesenchymal stem cells include an exogenous nucleic acid including (i) an Alpha-1 antitrypsin (AAT) encoding region operably linked to (ii) a promoter or promoter/enhancer combination.

A method for preparing an agonist for improving boar sperm motility includes: (1) collecting and infiltrating a testicular tissue of a young boar 3-5 days after born; (2) washing the tissue with PBS; (3) incubating the tissue in a cell culture medium, and centrifuging the cell suspension to remove a supernatant; (4) adding hyaluronidase and collagenase IV followed by shaking, and adding the cell culture medium and centrifuging to remove a supernatant; (5) adding trypsin and deoxyribonuclease followed by shaking, and adding the cell culture medium; (6) filtering the cell suspension by a cell sieve; (7) centrifuging to remove a supernatant, and adding the cell culture medium; (8) culturing and passaging the cells; (9) culturing and storing the cell suspension. The invention has the advantages of good application effect, low cost and simple production process.

A process for the preparation of chondrocyte cell suspension and its use in defect site of knee or ankle or shoulder or wrist or elbow or hip of subject.

The present invention aims to provide a method for producing a cartilage tissue, which enables production of a cartilage tissue having an appropriate thickness, form, and mechanical strength, and a cartilage tissue produced by the method for producing a cartilage tissue. Provided is a method for producing a cartilage tissue including a step of seeding a collagenase-treated cartilage tissue piece in the form of a block 50 to 1,000 m on a side onto a porous substrate composed of a bioabsorbable material.

The present invention relates to a pharmaceutical composition for preventing or treating chronic pulmonary disease, a pharmaceutical formulation containing the same, and a method for preparing the same, the composition comprising as an active ingredient an exosome derived from thrombin-treated stem cells. The therapeutic agent is advantageous in that since the therapeutic agent is a cell-free preparation, the risk of carcinogenesis is low and there is no problem of transplant rejection reaction, and furthermore, there is no possibility of causing the occlusion of the microvascular system upon systemic administration, and since the therapeutic agent is a non-cell separating material, it is possible to develop a pharmaceutical agent as an off-the-shelf product, thereby reducing the manufacturing cost, and the therapeutic agent has an excellent therapeutic effect for chronic pulmonary disease with a low concentration of exosome by virtue of the thrombin treatment effect.

A unified cell differentiation protocol for obtaining photoreceptor cells, retinal pigment epithelium, and 3D retinal organoid from pluripotent stem cells is described. Also described are photoreceptor cells, retinal pigmented epithelium, and 3D retinal organoid obtained from pluripotent stem cells. Also described are a pharmaceutical composition and a medicament containing the photoreceptor cells, retinal pigment epithelium, and 3D retinal organoid as described.

Embodiments of the present invention relate to compositions and methods for treatment of subjects in need of or having a bone marrow transplant. Certain embodiments describe compositions and methods for treatment of conditions associated with bone marrow transplantations in a subject, for example, Graft versus Host Disease (GvHD) or bone marrow transplantation rejection. Some embodiments concern early or immediate bone marrow transplantation rejection. Certain embodiments relate to compositions and uses of alpha1-antitrypsin (1-antitrypsin, AAT) and carboxyterminal peptide derivatives thereof and/or compositions and uses of serine protease inhibitors, immunomodulators or anti-inflammatory agent activity similar to that of AAT.

An object of the present invention is to prepare a functional intestinal organoid from pluripotent stem cells. An intestinal organoid is prepared from pluripotent stem cells, by the following steps (1) to (4): (1) differentiating pluripotent stem cells into endoderm-like cells; (2) differentiating the endoderm-like cells obtained in step (1) into intestinal stem cell-like cells; (3) culturing the intestinal stem cell-like cells obtained in step (2) to form spheroids; and (4) differentiating the spheroids formed in step (3) to form an intestinal organoid, the step including culture in the presence of a MEK1/2 inhibitor, a DNA methylation inhibitor, a TGF- receptor inhibitor, and a -secretase inhibitor, in addition to an epidermal growth factor, a BMP inhibitor, and a Wnt signal activator.